Danish biopharma giant Novo Nordisk (NOV: N) is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage ...
Anne-Marie Zanzal, 60, and her wife Tonda McKay, 62, have also experienced the more positive changes that weight-loss drugs ...
A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.